12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga · 10/02 21:06
Gainers
- American Shared Hospital (AMEX:AMS) shares rose 2.0% to $2.5 during Thursday's after-market session. The market value of their outstanding shares is at $16.1 million.
- AMN Healthcare Services (NYSE:AMN) shares increased by 1.99% to $19.94. The company's market cap stands at $765.3 million.
- Alto Neuroscience (NYSE:ANRO) stock moved upwards by 1.81% to $4.49. The market value of their outstanding shares is at $110.2 million.
- Protalix BioTherapeutics (AMEX:PLX) stock rose 1.7% to $2.38. The company's market cap stands at $188.1 million.
- cbdMD (AMEX:YCBD) shares increased by 1.69% to $1.2. The company's market cap stands at $10.1 million.
- MAIA Biotechnology (AMEX:MAIA) stock increased by 1.66% to $1.83. The company's market cap stands at $54.7 million.
Losers
- ADC Therapeutics (NYSE:ADCT) stock declined by 2.0% to $3.9 during Thursday's after-market session. The company's market cap stands at $449.9 million.
- PACS Group (NYSE:PACS) shares decreased by 1.99% to $13.85. The market value of their outstanding shares is at $2.1 billion.
- Emergent BioSolutions (NYSE:EBS) shares declined by 1.53% to $9.05. The market value of their outstanding shares is at $498.8 million.
- Theriva Biologics (AMEX:TOVX) stock decreased by 1.46% to $0.4. The market value of their outstanding shares is at $3.8 million.
- Myomo (AMEX:MYO) stock fell 1.44% to $0.9. The market value of their outstanding shares is at $34.5 million.
- Cigna Group (NYSE:CI) shares declined by 1.35% to $292.99. The market value of their outstanding shares is at $77.8 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.